30-Month Stay Proposal Would Delay Generics, Should Be Withdrawn, GPhA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed rule on 30-month stays would discourage timely suits by brand-name firms and should not be implemented, according to the Generic Pharmaceutical Association
You may also be interested in...
Hatch/Waxman Reform Bill Needed Despite FDA Rule – McCain, Schumer
Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said
Hatch/Waxman Reform Bill Needed Despite FDA Rule – McCain, Schumer
Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said
Hatch/Waxman Reform Bill Needed Despite FDA Rule – McCain, Schumer
Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said